Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Esperion Therapeutics, Inc. (NASDAQ: ESPR).

Full DD Report for ESPR

You must become a subscriber to view this report.


Recent News from (NASDAQ: ESPR)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR) between February 22, 2017 and May 1, 2018 . You are hereby notified that a s...
Source: Business Wire
Date: May, 17 2018 15:03
ESPR REMINDER: Pawar Law Reminds Investors of Important July 6, 2018 Lead Plaintiff Deadline in Class Action- ESPR
NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Pawar Law Group reminds shareholders who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) from February 22, 2017 through May 1, 2018, both dates inclusive (the "Class Period") of the important July 6, 2018 lead plaintiff deadline in th...
Source: ACCESSWIRE IA
Date: May, 17 2018 14:10
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Esperion Therapeutics, Inc. ("Esperion") (NASDAQ:ESPR) between February 22, 2017 and May 1, 2...
Source: GlobeNewswire
Date: May, 16 2018 17:47
Esperion Therapeutics (ESPR) Presents At Bank Of America Merrill Lynch 2018 Healthcare Conference - Slideshow
The following slide deck was published by Esperion Therapeutics in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 16 2018 14:40
ESPR ALERT: Rosen Law Firm Reminds Esperion Therapeutics, Inc. Investors of Important July 6 Deadline in Class Action
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Esperion Therapeutics, Inc. (NASDAQ:ESPR) from February 22, 2017 through May 1, 2018, both dates inclusive (the “Class Period”) of the important July 6, 2018 lead plaintiff deadline in th...
Source: Business Wire
Date: May, 16 2018 11:52
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2018 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Esperion Therapeutics, Inc. ("Esperion" or ''the Company'') (NASDAQ: ESPR ) for violations of §§10(b) and 20(a...
Source: ACCESSWIRE IA
Date: May, 15 2018 22:34
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
The Klein Law Firm announces the commencement of an investigation of Esperion Therapeutics, Inc. (NASDAQGM:ESPR) concerning possible violations of federal securities laws. On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication bem...
Source: Business Wire
Date: May, 15 2018 15:05
DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. - ESPR
RADNOR, Pa., May 14, 2018 (GLOBE NEWSWIRE) -- Kaskela Law LLC alerts Esperion Therapeutics, Inc. (NASDAQ:ESPR) (“Esperion” or the “Company”) shareholders that a class action lawsuit has been filed on behalf of purchasers of the Company’s securities betwe...
Source: GlobeNewswire
Date: May, 14 2018 17:21
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion Therapeutics, Inc. (ESPR)
The Klein Law Firm announces the commencement of an investigation of Esperion Therapeutics, Inc. (NASDAQGM: ESPR) concerning possible violations of federal securities laws. On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication be...
Source: Business Wire
Date: May, 14 2018 15:30
Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Esperion Therapeutics, Inc. (ESPR) and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all persons or entities who purchased or otherwise acquired Esperion Therapeutics, Inc. (NASDAQ: ESPR) securitie...
Source: Business Wire
Date: May, 14 2018 15:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1841.6142.7842.9541.09450,718
2018-05-1741.6142.7842.9541.09450,718
2017-02-0313.7716.4416.5013.40973,125,034
2017-02-0213.6112.7213.7312.48516,212
2017-02-0112.2413.5813.6512.111640,246

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1860,190163,13536.8958Short
2018-05-1755,940113,57649.2534Short
2018-05-1673,401180,13940.7469Short
2018-05-15140,066254,36755.0645Short
2018-05-14247,079411,87259.9893Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ESPR.


About Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Logo for Esperion Therapeutics, Inc. (NASDAQ: ESPR)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ESPR)

      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 11 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: ESPR)

      Daily Technical Chart for (NASDAQ: ESPR)


      Stay tuned for daily updates and more on (NASDAQ: ESPR)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ESPR)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      OTC Report
      @OTCReporter

       

       


      Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ESPR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ESPR and does not buy, sell, or trade any shares of ESPR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/